Trade Gyre Therapeutics Inc - GYRE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.1668 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 13.8366 |
| Open | 14.2266 |
| 1-Year Change | 2749.31% |
| Day's Range | 14.0266 - 14.3766 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 18, 2024 | 13.8366 | 0.0200 | 0.14% | 13.8166 | 14.8666 | 13.5966 |
| Sep 17, 2024 | 14.0466 | -0.0200 | -0.14% | 14.0666 | 14.7966 | 13.1266 |
| Sep 16, 2024 | 13.8966 | 0.3300 | 2.43% | 13.5666 | 14.4266 | 13.4366 |
| Sep 13, 2024 | 13.3866 | -0.4800 | -3.46% | 13.8666 | 13.8666 | 13.3766 |
| Sep 12, 2024 | 13.6366 | -0.1800 | -1.30% | 13.8166 | 13.9666 | 13.2666 |
| Sep 11, 2024 | 13.6966 | 0.7200 | 5.55% | 12.9766 | 13.8466 | 12.5666 |
| Sep 10, 2024 | 13.3117 | 0.8400 | 6.74% | 12.4717 | 13.3117 | 11.9717 |
| Sep 9, 2024 | 12.3117 | -0.2800 | -2.22% | 12.5917 | 12.8117 | 12.0617 |
| Sep 6, 2024 | 12.4617 | 0.6800 | 5.77% | 11.7817 | 12.6917 | 11.5717 |
| Sep 5, 2024 | 11.7617 | -0.5600 | -4.54% | 12.3217 | 12.3217 | 11.3017 |
| Sep 4, 2024 | 12.2017 | 0.2400 | 2.01% | 11.9617 | 12.6217 | 11.8617 |
| Sep 3, 2024 | 12.1417 | -1.5900 | -11.58% | 13.7317 | 13.7317 | 11.9017 |
| Aug 30, 2024 | 13.4917 | 0.0300 | 0.22% | 13.4617 | 13.8117 | 13.1017 |
| Aug 29, 2024 | 13.3817 | 0.2100 | 1.59% | 13.1717 | 13.7317 | 12.6117 |
| Aug 28, 2024 | 13.0817 | 0.7200 | 5.82% | 12.3617 | 13.4017 | 12.0717 |
| Aug 27, 2024 | 12.2817 | -1.6800 | -12.03% | 13.9617 | 14.7417 | 12.2117 |
| Aug 26, 2024 | 13.8617 | 1.1500 | 9.05% | 12.7117 | 14.6817 | 12.6617 |
| Aug 23, 2024 | 12.6617 | 1.2000 | 10.47% | 11.4617 | 12.9017 | 11.3717 |
| Aug 22, 2024 | 11.4117 | -0.4000 | -3.39% | 11.8117 | 11.9717 | 11.3717 |
| Aug 21, 2024 | 11.8017 | 0.1100 | 0.94% | 11.6917 | 12.0717 | 11.3717 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Catalyst Biosciences, Inc. Company profile
About Catalyst Biosciences Inc
Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Catalyst Biosciences Inc revenues decreased 74% to $4.9M. Net loss increased 81% to $67.6M. Revenues reflect License decrease from $15.1M to $0K. Higher net loss reflects Research and development increase of 3% to $38.3M (expense), General and administrative - Balancing v increase of 9% to $11.3M (expense), Miscellaneous income (expense) decrease of 99% to $8K (income).
Equity composition
Common Stock $.001 Par, 04/11, 100M auth., 29,021,460 issd., Insiders control approx. 0.08%. IPO: 4/06 5,000,000 shs. @ $9per share by Deutsche Bank Securities. 8/15, 1-for-7 reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
12770 High Bluff Drive, Suite 150
SAN DIEGO
CALIFORNIA 92130
US
News
BoE Preview: no change expected but forward guidance will be key
The BoE is forecasted to leave rates unchanged in September as UK CPI remains stubborn.
14:53, 19 September 2024
FOMC Decision Review: A 50 point cut but the markets responded in a mixed fashion
Discover the US Federal Reserve’s latest 50 basis point cut and how the markets reacted. Stocks surged, the US Dollar fell, and the Fed hints at more aggressive cuts ahead.
11:30, 19 September 2024
Bank of Japan Preview
The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.
09:40, 17 September 2024
FOMC Decision Preview
As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.
09:48, 16 September 2024
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com